Celsius Inc. (NASDAQ: CELH): Stephens started coverage with an Overweight rating and a $180 target price. The posted consensus target is $146.55. Friday’s final trade was reported at $150.10 a share.
Clorox Co. (NYSE: CLX): Zacks named this as its Bull of the Day stock. The analyst says it is more of an earnings growth story than a revenue growth story. Shares last closed at $156.14, which is up more than 11% year to date.
Fiserv Inc. (NASDAQ: FISV): B. Riley Securities initiated coverage with a Buy rating and a $148 price objective. The consensus target is $133.22, and the shares closed on Friday at $114.23.
Fortune Brands Innovations Inc. (NYSE: FBIN): J.P. Morgan resumed coverage with a Neutral rating. The firm also trimmed its $73 target price to $70, bringing it more in line with the $70.40 consensus target. Friday’s closing share price was $67.57.
Hain Celestial Group Inc. (NASDAQ: HAIN): Stephens started coverage with an Overweight rating and a $17 target price. The posted consensus target is $146.00. The final trade for Friday was reported at $150.10 a share.
Moderna Inc. (NASDAQ: MRNA): Though UBS upgraded the stock to Buy from Neutral, its $221 target price was reduced to $191. The consensus target is $197.49, and the shares closed on Friday at $118.50.
Planet Fitness Inc. (NASDAQ: PLNT): Exane BNP Paribas downgraded the shares from Neutral to Underperform with a $57 target price. The consensus target is $87.00. The stock closed over 3% lower on Friday at $65.70 due to the downgrade and the weak tape.
Principal Financial Group Inc. (NASDAQ: PFG): Jefferies upgraded the insurance and investment heavyweight to Hold from Underperform. Its $60 target price rose to $65 as well, but the consensus target is higher at $75.33. The close on Friday was at $72.40 a share.
Reinsurance Group of America Inc. (NYSE: RGA): Jefferies downgraded the stock to Hold from Buy and cut its $170 target price to $160. The consensus target is up at $169.08, and Friday’s close at $139.41 a share.
Sarepta Therapeutics Inc. (NASDAQ: SRPT): Evercore ISI downgraded the shares from Outperform to In line with a $139 target price. The consensus target is $174.26. On Friday, shares closed at $114.09, which was down close to 8% for the day despite a positive ruling from the FDA.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
